Last year, the World Health Organization (WHO) convened a gathering of experts, including
scientists, national regulatory authorities, industry representatives, epidemiologists and …

Human papillomavirus (HPV)-related morbidity and mortality from cervical cancer primarily
occurs in the developing world, where, unfortunately, access to vaccines in general, and …

Universal deployment of organized or opportunistic screening with Pap cytology in high and
middle income countries has been the primary reason for the substantial reductions in …

Despite the advent of the Papanicolaou smear test almost 50 years ago, cervical cancer
remains the second most common malignant disease in women and the leading cause of …

Cervical cancer is the most common cancer and a leading cause of cancer deaths among
women in developing countries. The disease is caused due to persistent infection of one or …

Human papillomavirus (HPV) vaccines for the prevention of cervical cancer have produced
encouraging results in recent clinical trials, and expectations are high that one or more …

Worldwide, cervical cancer is the second most common cancer of women. Less-developed
countries bear the greatest burden in terms of morbidity and mortality, largely due to the lack …

A wealth of evidence has led to the conclusion that virtually all cases of cervical cancer are
attributable to persistent infection by a subset of human papillomavirus (HPV) types …

Cervical cancer, the most common cancer affecting women in developing countries, is
caused by persistent infection with" high-risk" genotypes of human papillomaviruses (HPV) …

Cervical cancer is a critical public health issue in sub-Saharan Africa (SSA), where it is the
second leading cause of cancer among women and the leading cause of female cancer …